Plus Therapeutics Appoints Kyle Guse to Board

An update from Plus Therapeutics ( (PSTV) ) is now available.

On April 18, 2025, Plus Therapeutics, Inc. appointed Mr. Kyle Guse to its Board of Directors, filling the vacancy left by Mr. Greg Petersen’s resignation. Mr. Guse, who has extensive experience in finance, corporate governance, and law, will also serve on the Audit and Compensation Committees, and as Chairman of the Audit Committee. His appointment is seen as a strategic move to strengthen the company’s governance and financial oversight.

Spark’s Take on PSTV Stock

According to Spark, TipRanks’ AI Analyst, PSTV is a Underperform.

Plus Therapeutics faces significant financial challenges with consistent losses, negative equity, and cash flow difficulties. The promising clinical trials and successful financing offer some forward-looking optimism, yet the valuation remains a concern due to no earnings and lack of dividends. While technical indicators show neutral momentum, the company’s financial position requires strategic improvement.

To see Spark’s full report on PSTV stock, click here.

More about Plus Therapeutics

YTD Price Performance: -44.24%

Average Trading Volume: 16,241,334

Technical Sentiment Signal: Buy

Current Market Cap: $11.42M

Learn more about PSTV stock on TipRanks’ Stock Analysis page.